Tinnitus (Ear Nose Throat Disorders) – Drugs In Development, 2021

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Tinnitus – Drugs In Development, 2021, provides an overview of the Tinnitus (Ear Nose Throat Disorders) pipeline landscape.

Tinnitus is a condition characterized by ringing, swishing, or other noises that originating in the ear or head. Causes of tinnitus are age-related hearing loss, exposure to loud noises, earwax blockage in the ear canal, smoking and abnormal bone growth in the ear. Symptoms include ringing; buzzing, roaring, clicking, whistling, hissing, or squealing, noises may appear low or high in pitch.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Tinnitus – Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Tinnitus (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Tinnitus (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Tinnitus and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 1, 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.

Tinnitus (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

– The pipeline guide provides a snapshot of the global therapeutic landscape of Tinnitus (Ear Nose Throat Disorders).

– The pipeline guide reviews pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

– The pipeline guide reviews key companies involved in Tinnitus (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.

– The pipeline guide evaluates Tinnitus (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

– The pipeline guide reviews latest news related to pipeline therapeutics for Tinnitus (Ear Nose Throat Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Tinnitus (Ear Nose Throat Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Tinnitus (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Companies mentioned

AudioCure Pharma GmbH

Auris Medical Holding Ltd

Autifony Therapeutics Ltd

Cognosetta Inc

Gateway Biotechnology Inc

Knopp Biosciences LLC

Otonomy Inc

Sensorion SA

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Tinnitus - Overview

Tinnitus - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Tinnitus - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Tinnitus - Companies Involved in Therapeutics Development

AudioCure Pharma GmbH

Auris Medical Holding Ltd

Autifony Therapeutics Ltd

Cognosetta Inc

Gateway Biotechnology Inc

Knopp Biosciences LLC

Otonomy Inc

Sensorion SA

Tinnitus - Drug Profiles

AC-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AM-102 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AUT-3 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CS-0022 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Tinnitus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

esketamine hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

gacyclidine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GW-103 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GW-201 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KB-3061 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RL-81 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate KCNQ2 and KCNQ3 for Tinnitus - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tetrandrine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Tinnitus - Dormant Projects

Tinnitus - Discontinued Products

Tinnitus - Product Development Milestones

Featured News & Press Releases

Jun 16, 2021: Light E.N.T. announces first patient enrolled in drug trial for treatment of tinnitus (Ringing Sound in Ear)

Apr 05, 2021: Otonomy announces presentation of OTO-313 clinical results at American Neurotology Society Annual Meeting

Mar 25, 2021: Otonomy initiates phase 2 clinical trial of OTO-313 in Tinnitus

Nov 30, 2020: Otonomy provides update on OTO-313 program

Jul 06, 2020: Otonomy reports positive top-line results from phase 1/2 clinical trial of OTO-313 in patients with tinnitus

Jun 22, 2020: CogInc receives Bull Ring Accelerator Funding

Apr 08, 2020: CogInc awarded AOHL's Flexi grant

Jan 10, 2020: Auris Medical announces notice of allowance for European Patent Application

Dec 17, 2019: Cognosetta: SBIR grant awarded

Sep 13, 2019: Auris Medical receives FDA and EMA Guidance for Keyzilen late-stage clinical development program

Aug 26, 2019: Auris Medical announces formation of scientific advisory board for tinnitus programs

May 23, 2019: Auris Medical provides update on Keyzilen

Apr 25, 2019: Auris Medical provides update on Tinnitus Drug Development Strategy

Apr 11, 2019: Otonomy initiates phase 1/2 Clinical Trial of OTO-313 in Tinnitus

Feb 06, 2019: Otonomy announces presentation on tinnitus drug OTO-313 at Association for Research in Otolaryngology Annual Meeting

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Tinnitus, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Products under Development by Companies, 2021

Products under Development by Universities/Institutes, 2021

Number of Products by Stage and Target, 2021

Number of Products by Stage and Mechanism of Action, 2021

Number of Products by Stage and Route of Administration, 2021

Number of Products by Stage and Molecule Type, 2021

Tinnitus – Pipeline by AudioCure Pharma GmbH, 2021

Tinnitus – Pipeline by Auris Medical Holding Ltd, 2021

Tinnitus – Pipeline by Autifony Therapeutics Ltd, 2021

Tinnitus – Pipeline by Cognosetta Inc, 2021

Tinnitus – Pipeline by Gateway Biotechnology Inc, 2021

Tinnitus – Pipeline by Knopp Biosciences LLC, 2021

Tinnitus – Pipeline by Otonomy Inc, 2021

Tinnitus – Pipeline by Sensorion SA, 2021

Tinnitus – Dormant Projects, 2021

Tinnitus – Discontinued Products, 2021

List of Figures

List of Figures

Number of Products under Development for Tinnitus, 2021

Number of Products under Development by Companies, 2021

Number of Products under Development by Universities/Institutes, 2021

Number of Products by Targets, 2021

Number of Products by Stage and Targets, 2021

Number of Products by Mechanism of Actions, 2021

Number of Products by Stage and Mechanism of Actions, 2021

Number of Products by Routes of Administration, 2021

Number of Products by Stage and Routes of Administration, 2021

Number of Products by Stage and Molecule Types, 2021

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports